Management of osteoporosis

Clinical and Molecular Allergy

E Michael Lewiecki¹ 

[1] New Mexico Clinical Research & Osteoporosis Center, 300 Oak St. NE, Albuquerque, New Mexico 87106, USA

关键词: risk;    fracture;    glucocorticoid;    DXA;    bone density testing;    treatment;    management;    osteoporosis;   

Others  :  792797
DOI  :  10.1186/1476-7961-2-9

 received in 2004-05-12, accepted in 2004-07-14,  发布年份 2004

【 摘 要 】

Osteoporosis or osteopenia occurs in about 44 million Americans, resulting in 1.5 million fragility fractures per year. The consequences of these fractures include pain, disability, depression, loss of independence, and increased mortality. The burden to the healthcare system, in terms of cost and resources, is tremendous, with an estimated direct annual USA healthcare expenditure of about $17 billion. With longer life expectancy and the aging of the baby-boomer generation, the number of men and women with osteoporosis or low bone density is expected to rise to over 61 million by 2020. Osteoporosis is a silent disease that causes no symptoms until a fracture occurs. Any fragility fracture greatly increases the risk of future fractures. Most patients with osteoporosis are not being diagnosed or treated. Even those with previous fractures, who are at extremely high risk of future fractures, are often not being treated. It is preferable to diagnose osteoporosis by bone density testing of high risk individuals before the first fracture occurs. If osteoporosis or low bone density is identified, evaluation for contributing factors should be considered. Patients on long-term glucocorticoid therapy are at especially high risk for developing osteoporosis, and may sustain fractures at a lower bone density than those not taking glucocorticoids. All patients should be counseled on the importance of regular weight-bearing exercise and adequate daily intake of calcium and vitamin D. Exposure to medications that cause drowsiness or hypotension should be minimized. Non-pharmacologic therapy to reduce the non-skeletal risk factors for fracture should be considered. These include fall prevention through balance training and muscle strengthening, removal of fall hazards at home, and wearing hip protectors if the risk of falling remains high. Pharmacologic therapy can stabilize or increase bone density in most patients, and reduce fracture risk by about 50%. By selecting high risk patients for bone density testing it is possible to diagnose this disease before the first fracture occurs, and initiate appropriate treatment to reduce the risk of future fractures.

【 授权许可】

   
2004 Lewiecki; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 参考文献 】

• [1]Foundation National Osteoporosis: America's Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation. National Osteoporosis Foundation; 2002.
• [2]Melton LJ, III: How many women have osteoporosis now? J Bone Miner Res 1995, 10:175-177.
• [3]Melton LJ,III, Atkinson EJ, O'Connor MK, O'Fallon WM, Riggs BL: Bone density and fracture risk in men. J Bone Miner Res 1998, 13:1915-1923.
• [4]Melton LJ,III, Chrischilles EA, Cooper C, Lane AW, Riggs BL: Perspective. How many women have osteoporosis? J Bone Miner Res 1992, 7:1005-1010.
• [5]Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B: Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 2000, 11:669-674.
• [6]Jones G, Nguyen T, Sambrook PN, Kelly PJ, Gilbert C, Eisman JA: Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos Int 1994, 4:277-282.
• [7]Fast Facts on Osteoporosis National Institutes of Health Osteoporosis and Related Bone Disease National Resource Center; 1996.
• [8]Riggs BL, Melton LJ, 3rd: The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995, 17 (5 Suppl):505S-511S.
• [9]Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ,III: Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993, 137:1001-1005.
• [10]Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA: Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999, 353:878-882.
• [11]Ray NF, Chan JK, Thamer M, Melton LJ,III: Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the national osteoporosis foundation. J Bone Miner Res 1997, 12:24-35.
• [12]Klibanski A, Adams-Campbell L, Bassford T, Blair SN, Boden SD, Dickersin K, Gifford DR, Glasse L, Goldring SR, Hruska K, Johnson SR, McCauley LK, Russell WE, Osteopor NIH Consensus Dev Panel: Osteoporosis prevention, diagnosis, and therapy. JAMA 2001, 285:785-795.
• [13]Marshall D, Johnell O, Wedel H: Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996, 312:1254-1259.
• [14]Osteoporosis WHO Study Group on Assessment of Fracture Risk and its Application to Screening for Postmenopausal: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva, World Health Organization; 1994. [Technical report series 843]
• [15]Garnero P, Hausherr E, Chapuy M-C, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD: Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study. J Bone Miner Res 1996, 11:1531-1538.
• [16]Gnudi S, Malavolta N, Testi D, Viceconti M: Differences in proximal femur geometry distinguish vertebral from femoral neck fractures in osteoporotic women. Br J Radiol 2004, 77:219-223.
• [17]Myers ER, Wilson SE: Biomechanics of osteoporosis and vertebral fracture. Spine 1997, 22 (24 Suppl):25S-31S.
• [18]Heaney RP: Pathophysiology of osteoporosis. Endocrinol Metabol Clin North Am 1998, 27:255-265.
• [19]Bell KL, Loveridge N, Power J, Garrahan N, Meggitt BF, Reeve J: Regional differences in cortical porosity in the fractured femoral neck. Bone 1999, 24:57-64.
• [20]Burr D: Microdamage and bone strength. Osteoporos Int 2003, 14(Suppl 5):67-72.
• [21]Delmas PD: How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? Bone 2000, 27:1-3.
• [22]Boskey A: Bone Mineral Crystal Size. Osteoporos Int 2003, 14(Suppl 5):S16-S21.
• [23]Watts NB, Pols H, Ringe JD, Roux C, Horlait S, van de Langerijt L, Cahall DI, Delmas PD: Detection of "unexpected" osteoporosis: insights from the "IMPACT" trial. Arthritis Rheum 2001, 44:S256.
• [24]van Staa TP, Leufkens HGM, Cooper C: The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002, 13:777-787.
• [25]van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C: Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000, 15:993-1000.
• [26]van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C: Oral corticosteroids and fracture risk: relationship to daily and cumulative dosing. Rheumatology 2000, 39:1383-1389.
• [27]Luengo M, Picado C, Del Rio L, Montserrat JM, Setoain J: Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax 1991, 46:803-806.
• [28]Selby PL, Halsey JP, Adams KRH, Klimiuk P, Knight SM, Pal B, Stewart IM, Swinson DR: Corticosteroids do not alter the threshold for vertebral fracture. J Bone Miner Res 2000, 15:952-956.
• [29]van Staa TP, Leufkens HGM, Cooper C: Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001, 16:581-588.
• [30]Lipworth BJ: Systemic adverse effects of inhaled corticosteroid therapy, a systematic review and meta-analysis. Arch Intern Med 1999, 159:941-955.
• [31]Kemp JP, Osur S, Shrewsbury SB, Herje NE, Duke SP, Harding SM, Faulkner K, Crim CC: Potential effects of fluticasone propionate on bone mineral density in patients with asthma: a 2-year randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004, 79:458-466.
• [32]Allen DB: Systemic effects of intranasal steroids: an endocrinologist's perspective. J Allergy Clin Immunol 2000, 106:S179-S190.
• [33]Wolthers OD: Systemic activity versus systemic adverse effects of nasal glucocorticoids in the treatment of allergic rhinitis. Acta Paediatr 2000, 89:1158-1161.
• [34]Gudbjornsson B, Juliusson UI, Gudjonsson FV: Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis 2002, 61:32-36.
• [35]Patschan D, Loddenkemper K, Buttgereit F: Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone 2001, 29:498-505.
• [36]Leib ES, Lewiecki EM, Binkley N, Hamdy RC: Official positions of the International Society for Clinical Densitometry. J Clin Densitom 2004, 7:1-6.
• [37]Dawson-Hughes B, Harris SS, Krall EA, Dallal GE: Effects of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. N Engl J Med 1997, 337:670-676.
• [38]Chapuy MC, Arolt ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ: Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992, 327:1637-1642.
• [39]Foundation National Osteoporosis: Physician's guide to prevention and treatment of osteoporosis. Washington, D.C, National Osteoporosis Foundation; 2003.
• [40]Investigators Writing Group for the Women's Health Initiative: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002, 288:321-333.
• [41]Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L., Wactawski-Wende J, Wallace R, Wassertheil-Smoller S: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004, 291:1701-1712.
• [42]Osteoporosis American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced: Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2001, 44:1496-1503.
• [43]Wasnich RD, Miller PD: Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000, 85:231-236.
• [44]Riggs BL, Melton LJ,III: Bone turnover matters: The raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 2002, 17:11-14.
• [45]EM Lewiecki, LA Rudolph: How common is loss of bone mineral density in elderly clinical practice patients receiving oral bisphosphonate therapy for osteoporosis? J Bone Miner Res 2002, 17(Suppl 2):S367.
• [46]Lewiecki EM: Nonresponders to osteoporosis therapy. J Clin Densitom 2003, 6:307-314.
• [47]Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, Johnston CC,Jr., Kleerekoper M, Lindsay R, Luckey MM, McClung MR, Nankin HR, Petak SM, Recker RR, Anderson RJ, Bergman DA, Bloomgarden ZT, Dickey RA, Palumbo PJ, Peters AL, Rettinger HI, Rodbard HW, Rubenstein HA, AACE Osteoporosis Task Force: American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocrine Practice 2003, 9:544-564.
• [48]Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM: Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995, 332:767-773.